Cantor Fitzgerald Equities Analysts Lower Earnings Estimates for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) – Research analysts at Cantor Fitzgerald dropped their FY2021 earnings per share (EPS) estimates for shares of Aurinia Pharmaceuticals in a research note issued to investors on Tuesday, January 12th. Cantor Fitzgerald analyst A. Young now expects that the biotechnology company will post earnings per share of ($1.08) for the year, down from their prior forecast of ($0.81).

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Sunday, November 15th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.05). Aurinia Pharmaceuticals had a negative net margin of 173,992.23% and a negative return on equity of 36.98%. The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.06 million.

A number of other brokerages have also weighed in on AUPH. Zacks Investment Research upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. Bloom Burton lowered shares of Aurinia Pharmaceuticals from a “buy” rating to an “accumulate” rating in a research note on Tuesday, November 3rd. Oppenheimer restated a “buy” rating and set a $20.00 target price on shares of Aurinia Pharmaceuticals in a report on Thursday, December 17th. ValuEngine upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, December 17th. Finally, BidaskClub raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 1st. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $22.14.

AUPH opened at $13.89 on Thursday. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of -9.45 and a beta of 0.87. Aurinia Pharmaceuticals has a one year low of $9.83 and a one year high of $20.48. The business has a 50 day simple moving average of $14.12 and a two-hundred day simple moving average of $14.48.

Several hedge funds and other institutional investors have recently made changes to their positions in AUPH. Marshall Wace LLP purchased a new stake in shares of Aurinia Pharmaceuticals during the second quarter worth about $303,000. Advisor Group Holdings Inc. increased its stake in shares of Aurinia Pharmaceuticals by 136.5% in the second quarter. Advisor Group Holdings Inc. now owns 17,030 shares of the biotechnology company’s stock worth $277,000 after acquiring an additional 9,830 shares during the last quarter. Stifel Financial Corp raised its holdings in shares of Aurinia Pharmaceuticals by 102.6% during the second quarter. Stifel Financial Corp now owns 125,318 shares of the biotechnology company’s stock worth $2,036,000 after acquiring an additional 63,476 shares in the last quarter. Man Group plc raised its holdings in shares of Aurinia Pharmaceuticals by 277.2% during the second quarter. Man Group plc now owns 315,331 shares of the biotechnology company’s stock worth $5,124,000 after acquiring an additional 231,743 shares in the last quarter. Finally, Captrust Financial Advisors acquired a new stake in Aurinia Pharmaceuticals during the second quarter valued at $35,000. 51.21% of the stock is owned by institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

See Also: What are the benefits of momentum investing?